← Back to patent-cliff list
卡格列净/盐酸二甲双胍
Tier B — Position earlyCanagliflozin/Metformin Hydrochloride · all drugs expiring in 2029 →
强生创新制药
Originator
2014
First approval
2029
Expiry (public)
$1.11B ▲
Peak sales
化学药
Type
Targets：PRKAB1、SGLT2
Brand：Invokamet Xr、Vokanamet、Invokamet
Indications (approved)：终末期肾脏病、心脏和血管疾病、腹主动脉瘤、二型糖尿病
Regional status
US
批准上市
2014-08-08
EU
批准上市
2014-05-22
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Canagliflozin/Metformin Hydrochloride?
Approved indications include: 终末期肾脏病, 心脏和血管疾病, 腹主动脉瘤, 二型糖尿病.
When does the Canagliflozin/Metformin Hydrochloride patent expire?
Based on public sources, the Canagliflozin/Metformin Hydrochloride patent expires in 2029.
How do I get a quote for Canagliflozin/Metformin Hydrochloride intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24